Results 181 to 190 of about 1,812,118 (303)

In ovo model with emu eggs as novel alternative to animal testing in preclinical imaging research. [PDF]

EJNMMI Res
Perkas O, Pomraenke M, Porwoll V, Kühnel C, Wiegand S, Herrmann KH, Winkens T, Freesmeyer M.   +7 more
europepmc   +1 more source

Curated Data In - Trustworthy In Silico Models Out: The Impact of Data Quality on the Reliability of Artificial Intelligence Models as Alternatives to Animal Testing. [PDF]

Altern Lab Anim, 2021
Alves VM, Auerbach SS, Kleinstreuer N, Rooney JP, Muratov EN, Rusyn I, Tropsha A, Schmitt C.   +7 more
europepmc   +1 more source

Correlation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan‐cancer

Molecular Oncology, EarlyView.
PIK3R1 undergoes alternative splicing to generate the isoforms, p85α and p55α. By combining large patient datasets with laboratory experiments, we show that PIK3R1 spliced variants shape cancer behavior. While tumors lose the protective p85α isoform, p55α is overexpressed, changes linked to poorer survival and more pronounced in African American ...
Ishita Gupta, Yang Song, Madeleine Ndahayo, Anirudh Saxena, Theresa Guo, Dylan Z. Kelley, Jessica Gore, Andrew Hennigan, Alexa Anderson, John C. Papadimitriou, Daria A. Gaykalova   +10 more
wiley   +1 more source

Bioprinting for drug screening: A path toward reducing animal testing or redefining preclinical research? [PDF]

Bioact Mater
Budharaju H, Singh RK, Kim HW.
europepmc   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source

Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity

Molecular Oncology, EarlyView.
Von Locquenghien et al. report that MiTE‐144, a triggering receptor expressed on myeloid cells 2 (TREM2) blocking antibody fused to interleukin‐2 (IL2) variant with tumour microenvironment restricted activation, demonstrates superior anticancer efficiency in a preclinical setting.
Isaure Vanmeerbeek, Jenny Sprooten, Abhishek D. Garg   +2 more
wiley   +1 more source

Artificial intelligence-, organoid-, and organ-on-chip-powered models to improve pre-clinical animal testing of vaccines and immunotherapeutics: potential, progress, and challenges. [PDF]

Front Artif Intell
Elfatimi E, Lekbach Y, Prakash S, Karan S, Dorotta JC, Garcia A, Suoth BS, Maurya C, Omorogieva EY, Ng SXL, Liao EJ, Chow RA, BenMohamed L.   +12 more
europepmc   +1 more source

Computerized animal intelligence testing [PDF]

Behavior Research Methods & Instrumentation, 1972
John W. Davenport, Robert W. Benson, William W. Hagquist, Gene R. Rankin, Steven E. Shelton   +4 more
openaire   +1 more source

Colorectal cancer‐derived FGF19 is a metabolically active serum biomarker that exerts enteroendocrine effects on mouse liver

Molecular Oncology, EarlyView.
Meta‐transcriptome analysis identified FGF19 as a peptide enteroendocrine hormone associated with colorectal cancer prognosis. In vivo xenograft models showed release of FGF19 into the blood at levels that correlated with tumor volumes. Tumoral‐FGF19 altered murine liver metabolism through FGFR4, thereby reducing bile acid synthesis and increasing ...
Jordan M. Beardsley, Michael W. Rohr, Joseph A. Goode, Sai Preethi Nakkina, Jignesh G. Parikh, Deborah A. Altomare   +5 more
wiley   +1 more source

Maximizing Insights, Minimizing Animal Testing: A Framework for Validating Multiparametric Single-Cell Cytokine Analysis Panels. [PDF]

Eur J Immunol
Aleith J, Bergmann-Ewert W, Müller-Hilke B.   +2 more
europepmc   +1 more source